单孔机器人辅助袖状肺叶切除术:技术与结果
本研究基于前瞻性数据库纳入2022年1月至2025年6月连续134例接受单孔机器人辅助袖状肺叶切除术的患者,评估其安全性和可行性,并分析诱导治疗对围术期结局的影响。结果显示R0切除率97.8%,无30天死亡,诱导治疗延长手术时间和住院时间但不显著增加围术期风险。
要点
- 单孔机器人辅助袖状肺叶切除术技术安全可行,R0切除率高。
- 诱导治疗延长手术时间和住院时间,但不增加主要并发症或转开胸率。
- 诱导治疗后患者仍可考虑该术式,围术期风险可接受。
核心结论
- 单孔机器人辅助袖状肺叶切除术技术安全可行,R0切除率高,并发症可接受。
- 诱导治疗延长手术时间和住院时间,但不显著增加围术期风险。
研究设计与样本
- 前瞻性数据库纳入2022年1月至2025年6月连续134例接受单孔机器人辅助袖状肺叶切除术的患者,使用da Vinci Xi系统。
- 分析围术期变量包括患者特征、手术细节、病理结局和30天并发症,并比较诱导治疗与未诱导治疗患者。
主要发现
- 队列中位年龄62岁,72.3%有吸烟史,鳞状细胞癌占68.6%,55.2%接受诱导治疗(主要为化疗免疫治疗)。
- 左肺上叶是最常见切除部位(35.1%),R0切除率97.8%,中位手术时间185分钟,中位住院时间6天。
- 无30天死亡。
临床怎么用
- 单孔机器人辅助袖状肺叶切除术可用于复杂袖状肺叶切除,包括诱导治疗后的患者。
- 诱导治疗患者术后住院时间可能延长,应做好围术期管理预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to evaluate the safety and feasibility of uniportal robot-assisted thoracic surgery for sleeve lobectomy and to analyse the impact of induction therapy on perioperative outcomes. METHODS: Between January 2022 and June 2025, 134 consecutive patients who underwent uniportal robot-assisted thoracic surgery sleeve lobectomy using the da Vinci Xi system were enrolled from a prospective database. Perioperative variables, including patient characteristics, surgical details, pathologic outcomes, and 30-day complications, were analysed. Statistical comparisons were performed between patients who received induction therapy and those who did not. RESULTS: The cohort had a median age of 62 years, with 72.3% having a smoking history. Squamous cell carcinoma was predominant (68.6%), and 55.2% of patients received induction therapy, primarily chemoimmunotherapy. The left upper lobe was the most common resection site (35.1%). R0 resection was achieved in 97.8% of cases. The median operative time was 185 min, and median hospital stay was 6 days. Patients underwent induction therapy was associated with longer operative time (202.5 vs 172.5 min, P = .005) and hospital stay (7 vs 6 days, P < .001) but did not significantly affect blood loss, conversion rate (9.5% vs 6.7%, P = .687), major complications (23.0% vs 26.7%, P = .622), or 30-day readmission (1.4% vs 3.3%, P = .441). There were no 30-day deaths. CONCLUSIONS: Uniportal robot-assisted thoracic surgery sleeve lobectomy is technically safe and feasible, with high R0 rates and acceptable morbidity. Induction therapy prolongs operative time and hospitalization but does not significantly increase perioperative risk. These findings support the adoption of uniportal robot-assisted thoracic surgery for complex sleeve lobectomy, including patients after induction treatment.
引用
- Wang Z, Gonzalez-Rivas D, Yu J, et al. Uniportal Robotic-Assisted Sleeve Resections in a High-Volume Centre: Technique and Results. Eur J Cardiothorac Surg. 2026. PMID: 42102244. doi:10.1093/ejcts/ezag010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。